Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H37N3O5 |
Molecular Weight | 495.6105 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ONC(=O)CCCCCCC(=O)NC1=CC=C(CN[C@H](C(=O)OC2CCCC2)C3=CC=CC=C3)C=C1
InChI
InChIKey=GLNWREBYRLDPQP-MHZLTWQESA-N
InChI=1S/C28H37N3O5/c32-25(14-6-1-2-7-15-26(33)31-35)30-23-18-16-21(17-19-23)20-29-27(22-10-4-3-5-11-22)28(34)36-24-12-8-9-13-24/h3-5,10-11,16-19,24,27,29,35H,1-2,6-9,12-15,20H2,(H,30,32)(H,31,33)/t27-/m0/s1
Molecular Formula | C28H37N3O5 |
Molecular Weight | 495.6105 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tefinostat (also known as CHR-2845) was developed as an innovative oral HDAC (histone deacetylase) inhibitor that selectively targets macrophages and monocytes – central cells of the innate immune system. Chroma Therapeutics develops tefinostat for the treatment of hematological and lymphoid malignancies. In addition, the drug is under investigation in clinical trial phase I/II for cancer-associated inflammation in hepatocellular carcinoma. The aim of this study is to find the best dose of the drug without causing side effects. Besides, Phase II of clinical trial ‘MONOCLE’ study for the treatment of chronic myelomonocytic leukemia (CMML) has been initiated and the first patient has been recruited.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02759601
Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:39:40 GMT 2023
by
admin
on
Fri Dec 15 20:39:40 GMT 2023
|
Record UNII |
ZAU91150SB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1946
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000175925
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
914382-60-8
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
ZAU91150SB
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
DB15321
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
15940949
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
DTXSID00238568
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
9499
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY | |||
|
C152539
Created by
admin on Fri Dec 15 20:39:40 GMT 2023 , Edited by admin on Fri Dec 15 20:39:40 GMT 2023
|
PRIMARY |